Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.

ABSTRACT:

Background

Liver metastasis is the major cause of colorectal cancer related death. Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR) T-cell therapy has been illustrated effective and safe through regional delivery of breast cancer, ovarian cancer and malignant mesothelioma tumors. Herein, we investigated the safety, efficacy, and immune microenvironment of regional delivery of MSLN (CAR) T-cell in the treatment of colorectal carcinoma liver metastases (CRLM).

Methods

Second-generation MSLN CAR T-cells were administered by portal vein (PV) or caudal vein (CV, systemic administration) delivery in an orthotopic MSLN⁺ CRLM nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/γc^-/- (NSG) mouse model. A total of 20 mice were randomly divide

SUBMITTER: Zhou X 

PROVIDER: S-EPMC10932675 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature